Acenocoumarol

Anticoagulant
  • X
Routes of
administrationOralATC code
  • B01AA07 (WHO)
Legal statusLegal status
  • UK: POM (Prescription only)
Pharmacokinetic dataMetabolismHepaticElimination half-life8 to 11 hoursIdentifiers
  • (RS)-4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
CAS Number
  • 152-72-7 checkY
PubChem CID
  • 9052
DrugBank
  • DB01418 checkY
ChemSpider
  • 10443441 checkY
UNII
  • I6WP63U32H
KEGG
  • D07064 checkY
ChEBI
  • CHEBI:53766 checkY
ChEMBL
  • ChEMBL397420 checkY
CompTox Dashboard (EPA)
  • DTXSID2022541 Edit this at Wikidata
ECHA InfoCard100.005.281 Edit this at WikidataChemical and physical dataFormulaC19H15NO6Molar mass353.330 g·mol−13D model (JSmol)
  • Interactive image
ChiralityRacemic mixtureMelting point196 to 199 °C (385 to 390 °F)
  • CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(OC3=CC=CC=C3C2=O)O
  • InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3 checkY
  • Key:VABCILAOYCMVPS-UHFFFAOYSA-N checkY
  (verify)

Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is generic, so is marketed under many brand names worldwide.[1]

References

  1. ^ "International listings for acenocoumarol". Drugs.com.

Further reading

  • Cesar JM, García-Avello A, Navarro JL, Herraez MV (October 2004). "Aging and oral anticoagulant therapy using acenocoumarol". Blood Coagulation & Fibrinolysis. 15 (8): 673–676. doi:10.1097/00001721-200412000-00007. PMID 15613922. S2CID 19214006.
  • Lengyel M (December 2004). "[Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]". Orvosi Hetilap. 145 (52): 2619–2621. PMID 15724697.
  • Ufer M (2005). "Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol". Clinical Pharmacokinetics. 44 (12): 1227–1246. doi:10.2165/00003088-200544120-00003. PMID 16372822. S2CID 42970169.
  • Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J (April 2006). "The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients". British Journal of Haematology. 133 (2): 183–187. doi:10.1111/j.1365-2141.2006.06007.x. hdl:10171/21989. PMID 16611310. S2CID 369821.

External links

  • v
  • t
  • e
Antiplatelet drugs
Glycoprotein IIb/IIIa inhibitors
ADP receptor/P2Y12 inhibitors
Prostaglandin analogue (PGI2)
COX inhibitors
Thromboxane inhibitors
Phosphodiesterase inhibitors
Other
Anticoagulants
Vitamin K antagonists
(inhibit II, VII, IX, X)
Factor Xa inhibitors
(with some II inhibition)
Heparin group/
glycosaminoglycans/
(bind antithrombin)
Direct Xa inhibitors ("xabans")
Direct thrombin (IIa) inhibitors
Other
Thrombolytic drugs/
fibrinolyticsNon-medicinal
Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e